MJA
MJA InSight
MJA Careers
Editorials

Contemporary management of type 2 diabetes: blood glucose-lowering therapies and glycaemic targets

Timothy M E Davis
Med J Aust 2008; 189 (5): 246-248.

Recent trials and meta-analyses have raised questions about choice of therapy and use of strict glycaemic targets

Timothy M E Davis, DPhil, FRCP, FRACP, Professor of Medicine
School of Medicine and Pharmacology, University of Western Australia, Fremantle, WA.
Article References: 
Reference Text: 
Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49: 1711-1721.
Reference Order: 
1
PubMed ID: 
16802130
Reference Text: 
Ferrannini E. Response to comment on: Nathan DM, Buse JB, Davidson MB et al (2006). Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49: 1711–1721. Diabetologia 2007; 50: 1356-1357.
Reference Order: 
2
PubMed ID: 
Reference Text: 
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
Reference Order: 
3
PubMed ID: 
10938048
Reference Text: 
American Diabetes Association. Standards of medical care in diabetes — 2006. Diabetes Care 2006; 29 Suppl 1: S4-S42.
Reference Order: 
4
PubMed ID: 
Reference Text: 
Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
Reference Order: 
5
PubMed ID: 
17145742
Reference Text: 
Takeda Pharmaceuticals North America Inc. Observation of an increased incidence of fractures in female patients who received long-term treatment with Actos (pioglitazone HOI) tablets for type 2 diabetes mellitus. http://www.fda.gov/medwaTCH/safety/2007/Actosmar0807.pdf (accessed May 2007).
Reference Order: 
6
PubMed ID: 
Reference Text: 
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
Reference Order: 
7
PubMed ID: 
17517853
Reference Text: 
Dahabreh IJ. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Clin Trials 2008; 5: 116-120.
Reference Order: 
8
PubMed ID: 
18375649
Reference Text: 
Mannucci E, Monami M, Lamanna C, et al. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab 2008; May 26 [Epub ahead of print].
Reference Order: 
9
PubMed ID: 
Reference Text: 
Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: update regarding the thiazolidinediones. Diabetologia 2008; 51: 8-11.
Reference Order: 
10
PubMed ID: 
18026926
Reference Text: 
The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
Reference Order: 
11
PubMed ID: 
18539917
Reference Text: 
ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
Reference Order: 
12
PubMed ID: 
18539916
Reference Text: 
American Diabetes Association. Intense blood glucose control yields no significant effect on CVD reduction in VA Diabetes Trial [press release]. Alexandria, Va: ADA, 2008; 8 Jun. http://www.diabetes.org/for-media/pr-intense-blood-glucose-control-yields-no-significant-effect-on-cvd-reduction.jsp (accessed Jun 2008).
Reference Order: 
13
PubMed ID: 
Reference Text: 
Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
Reference Order: 
14
PubMed ID: 
16371630
Reference Text: 
Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes — an interim analysis. N Engl J Med 2007; 357: 28-38.
Reference Order: 
15
PubMed ID: 
17551159
Reference Text: 
Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591.
Reference Order: 
16
PubMed ID: 
18256393
Reference Text: 
American Diabetes Association. Statement from the American Diabetes Association related to the ACCORD trial announcement [press release]. Alexandria, Va: ADA, 2008; 6 Feb. http://www.diabetes.org/for-media/pr-ada-statement-related-to-accord-trail-announcement-020608.jsp (accessed May 2008).
Reference Order: 
17
PubMed ID: 

The full contents of this page are only available to subscribers.